An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
This is an open-label, single-arm, multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with TACE in the treatment of extrahepatic cholangiocarcinoma.
Extrahepatic Cholangiocarcinoma
DRUG: Toripalimab, Gemcitabine,Oxaliplatin
Progression-free survival, PFS is defined as time from the start of treatment to progression of disease or death., Up to 1 year
Objective response rate, The rate of participants that achieve either a complete response (CR) or a partial response (PR)., Up to 1 year|Disease control rate, The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable., Up to 1 year
This is an open-label, single-arm, multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with TACE in the treatment of extrahepatic cholangiocarcinoma.